Brief: Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026
25/06/2026 12:22
BRIEF-Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026 June 25 (Reuters) - Agenus Inc AGEN.O:
AGENUS ANNOUNCES THREE-YEAR SURVIVAL DATA FROM PHASE 1B BOT+BAL STUDY IN MSS METASTATIC COLORECTAL CANCER TO BE PRESENTED AT ESMO GI 2026
AGENUS ANNOUNCES THREE-YEAR SURVIVAL DATA FROM PHASE 1B BOT+BAL STUDY IN MSS METASTATIC COLORECTAL CANCER TO BE PRESENTED AT ESMO GI 2026
Source text: ID:nBwc9s1gGa
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income